Diabetes Product Articles & Analysis
10 news found
Destiny Pharma is developing the novel formulation of XF-73 Dermal for the prevention of infections associated with open wounds and broken skin including diabetic foot ulcers (DFUs) – up to 25% of US diabetic patients may suffer from DFUs in their lifetime and c. 13% have active ulcers. The XF-73 Dermal product is planned to be a fast, ...
Specifically, the patent allows for the innovative method of non-genetically modifying a cell population of human progenitor astrocytes or astrocytes, for use in the treatment or prevention of the progression of ALS in a human subject in need and screening an agent for preventing or treating Amyotrophic Lateral Sclerosis (ALS) by using this cell population. Kadimastem’s flagship ...
Biocon, which launched the world’s first interchangeable insulin Glargine in the US during the third quarter, has eight approved products. It has biosimilars in oncology like Pegfilgrastim, Trastuzumab, Bevacizumab and Pertuzumab, Adalimumab and Etanercept in immunology and diabetic products like Glargine, Aspart and RHI. ...
ByBiocon
Viatris and Biocon Biologics Ltd. launched their interchangeable Semglee® products (insulin glargine-yfgn) last month, which are the first, and currently the only, interchangeable biosimilars to Lantus®, providing more affordable options for the millions of Americans living with diabetes. ...
ByBiocon
(TASE: KDST), a clinical stage cell therapy company developing cell therapy treatments for ALS and diabetes, announced today that the Company held a preliminary meeting with the FDA (INTERACT) on October 7, 2021 regarding IsletRx, the company’s cell therapy product in development for the treatment of diabetes. ...
These capabilities are important in achieving the maximum therapeutic effect for potential future insulin-dependent diabetic patients. In addition, this method of production and cell selection enables the ILCs to be transplanted using a variety of platforms, including very small devices that are more suitable and more convenient for patients. ...
Specifically, the patent allows for the innovative method of non-genetically modifying a cell population of human progenitor astrocytes or astrocytes, for use in the treatment or prevention of the progression of ALS in a human subject in need and screening an agent for preventing or treating Amyotrophic Lateral Sclerosis (ALS) by using this cell population. Kadimastem’s flagship ...
Norwich, June 15 2020 – Ikarovec, which is developing novel gene therapies to treat major ophthalmic indications, has been awarded £458,740 by Innovate UK, the UK’s innovation agency, to accelerate development of its wet-form age- related macular degeneration (wAMD) product. The grant, made under the UKI2S Innovate Accelerator Programme, is being matched by ...
ByIkarovec
This year's cohort includes a diverse pool of companies that focus on every topic from diabetes monitoring to substance use treatment and workflow tools to senior ride sharing. ...
Based on its recent analysis of the diabetes point-of-care (POC) diagnostics market, Frost & Sullivan recognizes Epinex Diagnostics with the 2014 Global Frost & Sullivan Award for New Product Innovation. ...